Centro De Ingenieria Genetica Y Biotecnologia

Alicia Santos Savio

Osvaldo Reyes Acosta

Silvio Ernesto Perea Rodriguez

Haydee Geronimo Perez

Nelson Francisco Santiago Vispo

Yaquelin Puchades Izaguirre

Hilda Elisa Garay Perez

Ania Cabrales Rico

Yunier Rodriguez Alvarez

Celia Aurora Arrieta Aguero

Yanelis Morera Diaz

Ricardo Silva Rodriguez

Belkis Gonzalez Barrios

Belkis González Barrios

Luis Javier González López

Alejandro Moro Soria

Armando Alexei Rodriquez Alfonso

Jose Rafael Martinez Castillo

Luis Javier Gonzalez Lopez

Gerardo Enríque Guillen Nieto

Silvio Ernesto Perea Rodriquez

Yaquelín Puchades Izaguirre

The present invention is related to the field of molecular immunology, particularly to a peptide derived from the sequence of interleukine-15 (IL-15), wherein said peptide was optimized to inhibit the biological activity of this molecule. In the present invention, it is shown that this peptide inhibits IL-15-induced T cell proliferation, Tumor Necrosis Factor &#x3b1; (TNF&#x3b1;) induction and the expression of IL-8 and IL-6 by the IL-15 receptor &#x3b1; subunit (IL-15R&#x3b1;), all these effects mediated by the binding of the peptide to the IL-15R&#x3b1;. The invention is also related to the use of the peptide to treat pathologies where the abnormal expression of IL-15 or IL-15R&#x3b1; is related to the course of the disease, such as rheumatoid arthritis (RA) and prostate cancer.

Peptide antagonist of interleukin-15 activity

Vaccine composition containing IL-15 for active immunization to treatment diseases related to over-expression of this cytokine. The technical aim pursued in this invention is to inhibit IL-15 activity through development of a therapeutic vaccine which elicits IL-15 neutralizing antibodies in the immunized host. IL-15 can be presented in this vaccine composition either alone or coupled to a carrier such as the P64k protein with a vaccine adjuvant such as Aluminum hydroxide. Besides, this invention is related to the use of this vaccine for treatment of Rheumatoid arthritis and other IL-15 over-expressing related diseases, and leukemia, where this cytokine acts as a growth factor.

Vaccine composition comprising interleukin-15 (IL-15)

This invention is related to the Molecular Pharmacology field and especially to the development of peptides useful for treating epithelial tumors and mainly those associated to oncogenic types of HPVs. The main objective of this invention is to identify peptides whose structure permits to block the Casein Kinase II (CKII) phosphorylation domain by direct interaction with such a site. In the present invention it is shown eleven cyclic peptides with different aminoacid sequences which inhibit the CKII phosphorylation in vitro, exhibit cytotoxicity on HPV-16 transformed cells (CaSki) and also increase the sensitivity of these cells to the cytostatic effect of interferon (IFN). Furthermore, the invention relates to the use of these peptides conjugated or fused to other peptides and chemical compounds which penetrates into cells as well as with the use of both peptide and chemical mimetic molecules.

Peptides for the treatment of cancer associated with the human papilloma virus (HPV) and other epithelial tumors

Current invention is related to the molecular pharmacology branch particularly to a peptide belonging to the Interleukin-15 sequence (IL-15) which is able to inhibit IL-15 biological activity, analogues or mimetic of such peptides. In the current invention it is shown that the peptide inhibits both IL-15-induced T cells proliferation upon binding to the IL15 receptor a subunit (IL15R&#x3b1;) and TNF&#x3b1;-mediated apoptosis. Besides, this invention is related to the use of this peptide in the treatment of several pathologies where aberrant IL-15 or IL-15R&#x3b1; expression is associated to the disease progression.

Interleukin-15 antagonist peptide

Growing community of inventors

Ciudad de la Habana, Cuba

Alicia Santos Savio